Predictive Value Of Coexisting Kras And Tp53 Mutations On Response To Chemotherapy In Non-Small Cell Lung Cancer (Nsclc).

11060 Background: KRAS and TP53 are among the most common mutations in NSCLC. The LACE-Bio group evaluated coexisting KRAS/TP53 mutations in resected NSCLC and found chemotherapy to be deleterious in patients with double mutations. Methods: In an attempt to validate these results,NSCLC patients from Princess Margaret Cancer Centre who were tested for KRAS u0026 TP53 mutations and received chemotherapy for any stage NSCLC were selected. Mutation status was analyzed using Mi-SEQ or Sequenom platforms. TP53 analysis was added for DNA sequenced by Sequenom. Mutation status was correlated with clinical and demographic data. Relapse- or progression-free survival (RFS, PFS) was the main endpoint. Results: Among 186 patients identified, 24 had coexisting KRAS/TP53 mutations, 67 TP53, 27 KRAS; 68 had no KRAS or TP53 mutation (WT/WT). No difference was seen in age, sex or stage among the 4 populations (p = 0.09, p = 0.23, p = 0.36, respectively). There were significantly more Caucasians (96 v 65%, p = 0.009), smokers (...